LMAT LeMaitre Vascular, Inc.

LeMaitre Vascular (LMAT) is drawing fresh attention after its shares closed at US$80.58, with recent returns showing modest gains over the past month and a decline over the past 3 months. Viewed over a longer stretch, LeMaitre Vascular’s 1 year total shareholder return is down 7.29%, even as the 3 year total shareholder return of 54.81% and 5 year total shareholder return of 56.88% point to earlier strength that has cooled with the recent 90 day share price pullback of 14.21% from current...

LeMaitre Vascular has delivered a 56.9% share price gain over the past five years, yet its recent flat patch raises a simple question for you as an investor. Are the cash flows from this medical device business strong and reliable enough to support where the stock trades today? That 56.9% move over five years puts real weight on whether LeMaitre Vascular's cash generation can support the value the market now assigns to the business. The company focuses on vascular devices that can support...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.

PAHC vs. LMAT: Which Stock Is the Better Value Option?

Riverwater Partners, an investment management company, released its ‘Small Cap Strategy’ Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined […]

Let’s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings season.

GEHC vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre’s second quarter was marked by strong organic revenue gains, led by robust growth in its Artegraft line and continued expansion across Europe and Asia. However, the quarter fell short of Wall Street’s revenue and profit expectations, which contributed to a negative market reaction. Management attributed the underperformance to a combination of adverse currency impacts, ongoing Middle East export delays, and supply constraints in cardiac allografts. CEO George LeMaitre highlighted that,

Artegraft sales surged 34% as gross margins expanded to 72.1%.

What the latest earnings and guidance mean for LeMaitre Vascular stock LeMaitre Vascular (LMAT) has attracted fresh attention after reporting second quarter 2026 results that included higher sales and net income, alongside new earnings guidance and an affirmed quarterly dividend. For the second quarter ended June 30, 2026, LeMaitre Vascular reported sales of US$70.38 million compared with US$64.23 million a year earlier. Net income was US$17.05 million compared with US$13.78 million in the...

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm […]

Moby summary of LeMaitre Vascular, Inc.'s Q2 2026 earnings call

LeMaitre Vascular Inc (LMAT) reports 10% organic sales growth and 23% EPS growth in Q2 2026, driven by Artegraft and margin expansion, despite FX headwinds and supply challenges.

LeMaitre Vascular (NASDAQ:LMAT) reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign exchange, Middle East export delays and cardiac allograft supply constraints weighed on sales relati

LeMaitre (LMAT) delivered earnings and revenue surprises of -8.64% and -1.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 million. Next quarter’s revenue guidance of $67.3 million underwhelmed, coming in 3% below analysts’ estimates. Its GAAP profit of $0.74 per share was 8.3% below analysts’ consensus estimates.

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Tuesday after market close. Here’s what you need to know.